Two posters presented at the 2024 American Society of Hematology meeting evaluated overall survival and cost-offset of covalent Bruton’s tyrosine kinase inhibitors (cBTKis) in patients with chronic ...
Two posters presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exhibition focused on overall survival associated with real-world treatment sequences in patients with chronic ...
Two thousand two hundred twelve study patients were, on average, 63.0 years old, 69.9% of them were men, and 61.9% had a nonsquamous cell carcinoma. During the 2 years after nivolumab treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results